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Abstract. 
 
Here we report that DNA decatenation is 
not a physical requirement for the formation of mam-
malian chromosomes containing a two-armed chromo-
 
some scaffold. 2-aminopurine override of G
 
2
 
 arrest 
imposed by VM-26 or ICRF-193, which inhibit topo-
isomerase II (topo II)–dependent DNA decatenation, 
results in the activation of p34
 
cdc2
 
 kinase and entry into 
mitosis. After override of a VM-26–dependent check-
point, morphologically normal compact chromosomes 
form with paired axial cores containing topo II and 
ScII. Despite its capacity to form chromosomes of nor-
mal appearance, the chromatin remains covalently 
complexed with topo II at continuous levels during G
 
2
 
 
arrest with VM-26. Override of an ICRF-193 block, 
which inhibits topo II–dependent decatenation at an 
earlier step than VM-26, also generates chromosomes 
with two distinct, but elongated, parallel arms contain-
ing topo II and ScII. These data demonstrate that DNA 
decatenation is required to pass a G
 
2
 
 checkpoint, but 
not to restructure chromatin for chromosome forma-
tion. We propose that the chromosome core structure is 
templated during interphase, before DNA decatena-
tion, and that condensation of the two-armed chromo-
some scaffold can therefore occur independently of the 
formation of two intact and separate DNA helices.
 
T
 
he
 
 proper segregation of genetic material during
mitosis in eukaryotes requires extensive condensa-
tion of DNA into discrete chromosomes, each con-
taining two sister chromatids. Results from diverse experi-
mental systems have supported the conclusion that DNA
topoisomerase II (topo II)
 
1
 
 plays an essential role both in
chromosome formation and in the separation of sister
chromatids. In G
 
2
 
, topo II catalyzes the unravelling of the
highly intertwined catenated sister chromatids that remain
at the end of replication. This task is accomplished through
a strand-passing activity, in which one double-stranded
DNA segment passes through a transient double-strand
break in another DNA duplex (Hsieh and Brutlag, 1980;
Liu et al., 1980; for review see Roca, 1995). After the
strand separation, topo II is required for the condensation
of the chromosome (Newport and Spann, 1987; Adachi
et al., 1991; Hirano and Mitchison, 1993). Finally, at the
onset of anaphase, linkages that remain between the sister
chromatids must be resolved by topo II–dependent DNA
decatenation to allow sister chromatid segregation (Holm
et al., 1985; Uemura et al., 1987; Downes et al., 1991;
Shamu and Murray, 1992).
While the role of topo II in sister chromatid separation
is clear, its role in chromosome condensation is not well
understood. In mammalian cells, topo II localizes to an ax-
ial core (Earnshaw and Heck, 1985; Taagepera et al., 1993)
or chromosome scaffold that maintains a chromosome-
like morphology in the absence of DNA (Adolph et al.,
1977; Earnshaw et al., 1985), suggesting a structural role
for topo II in chromosome formation. DNA condensation
has been accomplished in vitro by incubation of interphase
nuclei with mitotic extracts (Newport and Spann, 1987;
Adachi et al., 1991; Hirano and Mitchison, 1993), and topo
II is absolutely required for the condensation of nuclei in
these in vitro systems (Adachi et al., 1991; Hirano and
Mitchison, 1993). However, it is unclear whether topo II–
dependent decatenation of chromatin is a physical prereq-
uisite for chromosome condensation or if it is only re-
quired as a structural component of the chromosome during
condensation.
The problem can be rephrased as follows: How does the
information content for condensation of an organized
chromosome arise? It is possible that the decatenation of
chromatin strands is an obligatory step before chromo-
some condensation and that this event allows the indepen-
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dent duplexes to form two chromatid arms, each with an
axial core. Alternatively, it is possible that the information
necessary to form the two chromatids with axial cores has
been templated independently, and before, the decatena-
tion event.
Here we have approached the problem of the interde-
pendence of decatenation and chromatin condensation in
intact mammalian cells. Mammalian cells contain a check-
point that imposes G
 
2
 
 arrest and blocks progression into
mitosis if chromatin is not sufficiently decatenated (Downes
et al., 1994). A drug block with any of several agents that
interfere with topo II enzyme activity, such as VM-26 and
ICRF-193, imposes a checkpoint on cell cycle progression
in which the cell arrests in G
 
2
 
 with undecatenated DNA.
We have demonstrated, in a previous study, that when
mammalian cells were arrested in G
 
2
 
 with the topo II in-
hibitor VM-26, addition of the protein kinase inhibitor
2-aminopurine (2-AP) would override the drug block and
induce mitosis (Andreassen and Margolis, 1992). Strik-
ingly, we noted that the mitotic cells showed evidence of
chromosome condensation after checkpoint override. The
implication was that topo II–dependent decatenation of
DNA in G
 
2
 
 was not a physical prerequisite for the conden-
sation of mitotic chromosomes. By contrast, Downes et al.
(1994) found that complete chromosome condensation
was blocked by ICRF-193 after checkpoint override, leading
to the opposite conclusion that topo II–dependent decate-
nation of DNA is required for chromosome condensation.
In this report, we present a careful analysis of the forma-
tion of mitotic chromosomes during checkpoint override
in mammalian cells after G
 
2
 
 arrest with either of two topo
II inhibitors, VM-26 or ICRF-193. Our data demonstrate
that topo II–dependent decatenation is not required to re-
model chromatin into a condensed chromosome with two
axial cores. Further, the formation of two independent ax-
ial cores apparently does not require that intact and con-
tinuous DNA helices underlie them. Interestingly, while
VM-26 permits the formation of fully condensed chromo-
somes, ICRF-193, which interacts with topo II in a different
manner (Tanabe et al., 1991; Roca et al., 1994), results
in formation of chromosomes with paired, but highly
elongated, sister chromatids. It would thus appear that
ICRF-193, but not VM-26, interferes specifically with a
nonenzymatic topo II–dependent step leading to complete
chromosome condensation.
Since the formation of chromosome cores is indepen-
dent of decatenation, a template for the axial cores must
exist independently of the intact DNA helices. This prop-
erty requires that a template be formed before the G
 
2
 
 de-
catenation step, perhaps during DNA replication. We pro-
pose that assembly of the axial core, independent of DNA
decatenation, is required for the final steps of chromo-
some condensation, and we present a model in which the
association of topo II with replicated DNA prepares a
template for chromosome formation by assembly of the
axial core.
 
Materials and Methods
 
Cell Culture and Synchronization
 
CHO and BHK cells were grown as monolayers in DME (GIBCO BRL,
 
Paisley, UK) supplemented with 10% FBS (Biological Industries, Israel).
Cells were maintained in a humid incubator at 37
 
8
 
C in a 5% CO
 
2
 
 environ-
ment.
Nocodazole and hydroxyurea (HU) were obtained from Sigma Chemi-
cal Co. (St. Louis, MO). Stock solutions of 1 
 
m
 
g/ml nocodazole and 200
mM HU were prepared in DMSO and DME, respectively. VM-26 was ob-
tained from Bristol-Myers Squibb (Princeton, NJ) and prepared as a 5 mM
stock solution in DMSO. ICRF-193 was a gift from A.M. Creighton (St.
Bartholomew’s Hospital, London, UK), and was prepared as a stock solu-
tion in DMSO (70 mM). All stock solutions were kept frozen until used.
Synchronization of CHO cells just before G
 
2
 
 was initiated by treatment
with isoleucine-deficient DME containing 10% dialyzed FBS (GIBCO
BRL). Subsequently, cells were treated with 2 mM HU in complete me-
dium for 16 h and then released into drug-free medium for 5 h. Experi-
mental protocols involving treatment with VM-26 commenced at this
time.
 
Chromosome Spreads
 
Cells were grown as subconfluent monolayers for a minimum of 24 h be-
fore any drug treatment. Cells were then treated with 2 mM HU, 10 
 
m
 
M
ICRF, or VM-26 (0.20 
 
m
 
g/ml CHO; 0.02 
 
m
 
g/ml BHK) for 16 h. Where ap-
plicable, this was followed by 3 h of treatment with 10 mM 2-AP in the
continued presence of the first drug. Treatment with nocodazole was at a
concentration of 0.20 
 
m
 
g/ml for 3 h. To prepare chromosome spreads, cells
were collected and swollen with 10 mM Tris-HCl, pH 7.4, 10 mM NaCl,
and 5 mM MgCl
 
2
 
 for 5 min at room temperature (Earnshaw et al., 1985).
Cells were then pelleted 2 min at 215 
 
g
 
 and fixed for 30 min at room tem-
perature in methanol/acetic acid (3:1). Spreads were then obtained by dry-
ing the cell suspension on coverslips at 30
 
8
 
C. The chromosome prepara-
tion was then washed with PBS, stained for 5 min with 0.5 
 
m
 
g/ml
propidium iodide in PBS, washed again twice, and mounted for observation.
 
Immunofluorescence Microscopy
 
For immunofluorescence microscopy, cells were grown on 12-mm-diam
coverslips for a minimum of 24 h before drug treatment. For immunode-
tection of MPM-2 antigens (Davis et al., 1983), cells were fixed, permeabilized,
and prepared with primary and FITC-conjugated affinity purified anti–mouse
IgG secondary antibodies as previously described (Andreassen and Mar-
golis, 1994). Counterstain was with 0.5 
 
m
 
g/ml propidium iodide in PBS.
For immunolocalization of topo II and ScII, cells were swollen by addi-
tion of 50 
 
m
 
l of 0.8% sodium citrate to each coverslip for 10 min at room
temperature and were then fixed in 50% methanol/acetic acid (3:1) for 2
min, followed by 100% methanol/acetic acid (3:1) for 5 min as described
by Saitoh et al. (1994). Chromosome spreads were obtained by drying at
30
 
8
 
C. Preparations were then rehydrated by three washes of 2 min each in
TEEN (1 mM triethanolamine-HCl, pH 8.5, 0.2 mM EDTA, 25 mM
NaCl) containing 0.1% BSA and 0.5% Triton X-100 (Saitoh et al., 1994).
Primary antibodies were diluted in TEEN containing 0.1% BSA and 0.5%
Triton X-100 and were applied for 1 h at 37
 
8
 
C. Rabbit anti-human topo II
(TopoGEN Inc., Columbus, OH) and rabbit anti-ScII antisera 966 and
1113 (kind gifts of N. Saitoh and W.C. Earnshaw, Johns Hopkins Univer-
sity, Baltimore, MD) were diluted 200-fold. Chromosomes were then
washed three times, 5 min each, with KB
 
1
 
 buffer (10 mM Tris-HCl, pH
7.7, 150 mM NaCl, 0.1% BSA, 0.1% Triton X-100) (Saitoh et al., 1994).
FITC-conjugated affinity-purified goat anti–rabbit IgG antibodies (Cap-
pel Laboratories, West Chester, PA) were applied at 2.5 
 
m
 
g/ml in KB
 
1
 
buffer for 30 min at 37
 
8
 
C. Chromosomes were then washed twice for 5 min
each with KB
 
1
 
, counterstained 5 min with 0.5 
 
m
 
g/ml propidium iodide in
KB
 
1
 
, and finally washed twice with KB
 
1
 
.
Samples were observed using a microscope (model Optiphot II; Nikon
Inc., Melville, NY) attached to a laser scanning confocal apparatus (model
MRC-600, BioRad Microscience Division, Herts, England). Photographs
were taken on TMAX-100 film with a film recorder (model CI-3000; Po-
laroid Corp., Cambridge, MA).
 
Flow Cytometric Analysis
 
Cells were collected by trypsinization, pooled with nonattached cells, and
fixed 10 min with 90% methanol/PBS at 
 
2
 
20
 
8
 
C. Fixed cells were then in-
cubated with MPM-2 antibodies, washed, incubated with FITC-conju-
gated goat anti–mouse IgG secondary antibodies, and then incubated with
propidium iodide in 4 mM sodium citrate containing RNase A as previ-
ously described (Andreassen and Margolis, 1994). 
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Data were collected using a FACScan
 
®
 
 (Becton-Dickinson, San Jose, CA).
For each sample, 10,000 events were collected. Aggregated cells were gated
out and plots were prepared using LYSYS II software (Becton-Dickinson).
 
Histone H1 Kinase Assay
 
CHO cells were grown as subconfluent monolayers for a minimum of 24 h
before drug treatment. Cells were first treated for 16 h with 0.20 
 
m
 
g/ml
VM-26 and were then either cultured with medium containing 0.20 
 
m
 
g/ml
VM-26 plus 10 mM 2-AP or with VM-26 alone. At time points, the popu-
lation was harvested by trypsinization, and cell extracts were prepared in
lysis buffer (Andreassen and Margolis, 1994). Preclearing of proteins
binding nonspecifically to Sepharose 4B–protein A beads, incubation with
affinity-purified anti-p34
 
cdc2
 
 antibody, incubation with protein A–Sepha-
rose beads, washing of the resulting immune complex, and the kinase re-
action were performed as described previously (Andreassen and Margolis,
1994). Samples were then subjected to SDS-PAGE on 12% polyacrylamide
gels (19:1 ratio of acrylamide to bis-acrylamide), and autoradiographs
were prepared by exposure to Hyperfilm-MP (Amersham Corp., Arling-
ton Heights, IL).
 
Analysis of Covalent DNA–Topoisomerase
II Intermediates
 
Stabilization of the covalent DNA–topo II cleavage intermediate by VM-26
was measured using the In Vivo Link-Kit from TopoGEN Inc. Cells grow-
ing on 10-cm-diam culture dishes were synchronized just before G
 
2
 
 as de-
scribed above, and samples were prepared at time points after the intro-
duction of 0.20 
 
m
 
g/ml VM-26. For the assay, cells were lysed in 10 mM
Tris-HCl buffer at pH 7.5, containing 1 mM EDTA and 1% sarkosyl.
These conditions extract noncovalently linked topo II from the DNA.
Samples were then applied to a cesium chloride step gradient containing
0.20 
 
m
 
g/ml VM-26 and centrifuged to separate DNA from free protein
(Trask and Muller, 1988). Fractions of 400 
 
m
 
l each were collected from the
gradients, and 50 
 
m
 
l samples from each fraction were diluted with 100 
 
m
 
l
of 25 mM sodium phosphate (pH 6.5) and applied to nitrocellulose using a
Hybri-Dot manifold (GIBCO BRL). The nitrocellulose membrane was
incubated 2 h with TBS-Tween (20 mM Tris-HCl, pH 7.6, 137 mM NaCl,
0.1% Tween 20) containing 5% nonfat powdered milk and subsequently
washed three times for 10 min each with TBS-Tween. Incubation with
rabbit anti–human topo II antibody (TopoGEN Inc.) diluted 2,500-fold in
TBS-Tween was carried out for 3 h at ambient temperature. After three
washes with TBS-Tween, the dot blots were developed with enhanced
chemiluminescence (Amersham Corp.). Levels of topo II covalent inter-
mediates in the fractions were quantitated using a Vista-S6 scanner cou-
pled to a Macintosh computer and NIH Image software to integrate the
signals in the fractions containing DNA. The DNA peak was located and
quantitated by staining with 10 
 
m
 
g/ml Hoechst 33258, followed by mea-
surement of fluorescence on an Aminco-Bowman Series 2 luminescence
spectrophotometer (SLM-Aminco, Rochester, NY), using an excitation
wavelength of 365 nm and an emission wavelength of 460 nm.
 
Pulsed Field Gel Electrophoresis
 
Cells treated with 2-AP, or with VM-26 alone, were collected as whole cell
populations by trypsinization. For those culture dishes treated with VM-26
plus 2-AP, mitotic cells were selectively detached from the culture dish at
3 h after 2-AP addition, resulting in a mitotic index of at least 85% in the
harvested cells. Preparation of agarose plugs from cells and further treat-
ment was according to Filipski et al. (1990). Cells were resuspended in 1.0
ml of nuclear buffer (2 mM KH
 
2
 
PO
 
4
 
, pH 6.4, 150 mM NaCl, 1 mM EGTA,
5 mM MgCl
 
2
 
) and were then counted and resuspended at 3–5 
 
3
 
 10
 
7
 
 cells/
ml in the same buffer depending on the experiment. An equal volume of
molten 1.5% low–melting point agarose in nuclear buffer, also containing
0.4 mg/ml proteinase K, was then added to each sample. The mixture was
injected into Tygon tubing (1/16 inch internal diameter) using a syringe
with an 18-gauge needle and was solidified for 30 min on ice. Samples
were then incubated in 10 mM Tris-HCl, pH 9.5, 10 mM NaCl, 25 mM
EDTA, and 10% sarkosyl containing 33 
 
m
 
g/ml proteinase K for 18 h at
37
 
8
 
C, and then samples were washed thoroughly in 10 mM Tris-HCl, pH
8, and 1 mM EDTA at 4
 
8
 
C. For cell populations exposed to VM-26 either
with or without 2-AP, all incubations and washes contained 0.20 
 
m
 
g/ml VM-
26 to inhibit decatenation during processing.
Pulsed field gel electrophoresis was performed using a horizontal gel
electrophoresis chamber (Pharmacia LKB Biotechnology, Piscataway, NJ)
and a power inverter (model PPI-200; MJ Research, Watertown, MA).
Molecular weight standards were 
 
l
 
 phage oligomeric DNA (50–700 kb)
and 
 
S. cerevisiae
 
 chromosomal DNA (225–2,200 kb) supplied by BioRad
Laboratories (Hercules, CA). Samples were sealed in place with LMP
agarose in a 1% pulsed field grade agarose gel and were run at 8 V/cm
with 0.5 
 
3
 
 TBE. After 10 min, ramping began at 0.39 s in the forward di-
rection and 0.13 s in the reverse direction, with 56 increments of 0.15 and
0.05 s, respectively. The total run time was 8 h. Chamber temperature was
maintained at 23
 
8
 
C during the run, using a refrigerated circulating water
bath (model DC3; HAAKE/Fisons Instruments, Valencia, CA). After
completion of the run, photographs of gels were taken under UV light us-
ing Polaroid 667 film.
 
Chromosome/Nuclear Isolation and Immunoblotting
 
Chromosome clusters were isolated from selectively detached mitotic
cells, which were washed three times with PBS at 4
 
8
 
C. For this, cells were
lysed and chromosomes were separated according to the technique of Sai-
toh and Laemmli (1994). Nuclei were similarly isolated after collection by
trypsinization.
Samples were equalized on the basis of DNA content measured by ab-
sorbance at 260 nm. Electrophoresis on 8% polyacrylamide gels, transfer
to nitrocellulose, and development with enhanced chemiluminescence
(Amersham Corp.) were as previously described (Andreassen and Mar-
golis, 1994). Anti-ScII antiserum 966 and anti–topo II antibodies (Topo-
GEN Inc.) were used at dilutions of 5,000- and 3,000-fold, respectively.
 
Results
 
VM-26 inhibits topo II–dependent DNA strand passage
activity, blocking the reaction at a step where the enzyme
forms a covalent intermediate with a cleaved DNA double
strand (Chen et al., 1984). This drug induced block results
in G
 
2
 
 arrest in mammalian cells (Misra and Roberts, 1975;
Charron and Hancock, 1990). We have verified by flow cy-
tometric analysis that 16 h of VM-26 treatment results in
arrest of CHO cells in G
 
2
 
 with 4N DNA content (Fig. 1 
 
A
 
,
 
left
 
). By contrast, untreated cycling CHO cells display a
predominantly 2N DNA content.
MPM-2 antibodies recognize mitosis-specific phospho-
epitopes (Davis et al., 1983). Using these antibodies, mi-
totic cells can be distinguished as the subset of cells that
displays an elevated MPM-2 signal when analyzed by two-
dimensional flow cytometry (Fig. 1 
 
A
 
, 
 
right
 
). Among the
cells with a 4N DNA content in an untreated cycling CHO
population, a subset have an elevated MPM-2 signal.
These represent the mitotic cells. Almost all cells after
treatment for 16 h with 0.20 
 
m
 
g/ml (0.31 
 
m
 
M) VM-26 have
a 4N DNA content. As expected of G
 
2
 
-arrested cells, this
population has a minimal MPM-2 signal. The VM-26–
induced arrest in G
 
2
 
 is solid, as CHO cells remain arrested
in G
 
2
 
 with 4N DNA content and exhibit a minimal MPM-2
signal through 24 h of treatment (data not shown). Cells
arrested in G
 
2
 
 by treatment for 16 h with VM-26 can be in-
duced to enter mitosis by addition of 10 mM 2-AP in the
continued presence of VM-26. While the cells maintain a
4N content of DNA, entry into mitosis is evident from the
induction of an elevated MPM-2 signal, as measured by
two-dimensional flow cytometry (Fig. 1 
 
A
 
, 
 
right
 
).
The time course of override of VM-26–induced G
 
2
 
 ar-
rest by 2-AP was quantitated as the percentage of the
whole cell population that entered mitosis, by immunoflu-
orescence microscopic assay (Fig. 1 
 
B
 
). In this assay, we
scored cells as mitotic if they displayed both an elevated
MPM-2 signal and condensed chromatin. By immunofluo-
rescence assay, cells arrested in G
 
2
 
 after 16 h treatment 
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Figure 1. 2-AP overrides VM-26–induced G2 arrest in CHO cells. (A) Histograms of DNA content (left) and two-dimensional dot plots
of MPM-2, a mitosis-specific phosphoepitope, versus DNA content (right). In comparison to untreated controls, 16 h of treatment with
0.20 mg/ml VM-26 results in accumulation of cells in G2 with 4N DNA content and low MPM-2 signal. Addition of 10 mM 2-AP during
continuous exposure to VM-26 induces entry into mitosis, as indicated by the accumulation of cells with an elevated MPM-2 signal. (B)
Quantitation of mitotic entry induced by 2-AP. Quantitation was performed by microscopy, counting cells that were both positive for
MPM-2 and for chromatin condensation, as visualized with propidium iodide. Cells were synchronized in G2 by 16 h of exposure to VM-
26 and were subsequently exposed to both VM-26 and 2-AP or were continued in VM-26 alone. All points represent the average of
three counts of at least 250 cells each. Standard deviation was ,1.2% of the ordinate scale for each value. (C) Micrographs showing the
MPM-2 immunofluorescence image of cells treated with VM-26 (top) or with both VM-26 and 2-AP (bottom). MPM-2 levels are low in
interphase cells, which are identified by the presence of propidium iodide stained nuclei (right). In contrast, MPM-2 levels are elevated
in mitotic cells, also containing condensed chromatin, after induction by 2-AP. (D) Assay of p34cdc2 activity in cells arrested in G2 with
VM-26, and in VM-26–treated cells induced to enter mitosis with 2-AP. Cells were pretreated with VM-26 for 16 h before the time
points of the assay. Bar, 5 mm. 
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with 0.20 
 
m
 
g/ml VM-26 display a low MPM-2 signal (Fig. 1, 
 
B
 
and 
 
C
 
, 
 
top
 
). These cells also contain intact interphase nu-
clei, as determined by propidium iodide counterstain. Af-
ter addition of 2-AP in the continued presence of VM-26,
mitotic cells with high MPM-2 levels and condensed chro-
matin first become apparent within 2 h, and the number of
mitotic cells peaks after 3 h of exposure to both VM-26
and 2-AP. A micrograph (Fig 1 
 
C
 
, 
 
bottom
 
) displays a typi-
cal mitotic cell, containing both a high MPM-2 signal and
condensed chromatin, that is scored positive in this assay.
By contrast, a cell treated with VM-26 alone, as shown,
displays low MPM-2 signal and has an intact interphase
nucleus.
Activation of p34
 
cdc2
 
 kinase is required to induce entry
into mitosis in eukaryotes (Norbury and Nurse, 1992). As
a further measure of the ability of 2-AP to induce mitotic
entry after G
 
2
 
 checkpoint override, we have assayed
p34
 
cdc2
 
 kinase activity at time points during exposure to ei-
ther VM-26 alone or to VM-26 in combination with 2-AP
(Fig. 1 
 
D
 
). Elevation of p34
 
cdc2
 
 activity was detectable after
VM-26 arrested cells were exposed to 2-AP for 2 h and
peaked at 3 h after 2-AP exposure. This result correlates
well with the time course of mitotic entry as demonstrated
by quantitative analysis using immunofluorescence mi-
croscopy (Fig. 1 
 
B
 
). In contrast, p34
 
cdc2
 
 activity was not el-
evated at any time point during continued exposure to
VM-26 alone (Fig. 1 
 
D
 
).
It is evident, as we have previously reported (Andreas-
sen and Margolis, 1992), that chromatin becomes con-
densed when cells enter mitosis after 2-AP–induced over-
ride of G
 
2
 
 arrest (Fig. 1 C, bottom). To carefully examine
the state of chromosome condensation and formation in
these cells, we have prepared chromosome spreads from
cells treated with both VM-26 and 2-AP (Fig. 2 A). Re-
peatedly, we have found that condensed chromosomes
that are apparently normal in morphology are formed af-
ter 2-AP–induced override of G2 arrest with VM-26. The
level of condensation is equivalent to chromosomes in
control cells arrested in mitosis with nocodazole. 2-AP–
induced chromosomes resemble normal prophase chro-
mosomes (Sumner, 1991) in that their chromatid arms re-
main largely unseparated. In contrast, chromosomes
formed in the presence of nocodazole contain two well-
separated chromatid arms. Chromatin condensation and
chromosome formation results from 2-AP–induced over-
ride of the G2 arrest, since only interphase nuclei are
present in cells treated for an equivalent period of time
with VM-26 alone.
The formation of intact chromosomes during checkpoint
override with 2-AP is specific to G2 arrest with VM-26. By
comparison, formation of intact chromosomes does not
occur in S-phase checkpoint override. It has previously
been reported that premature progression to mitosis in the
absence of completed DNA replication results in severe
fragmentation of chromosomes (premature chromosome
condensation [PCC]) (Johnson and Rao, 1970; Schlegel
and Pardee, 1986). In accord with those results, we have
also found that override of HU-induced S-phase arrest by
2-AP results in PCC (Fig. 2 A).
Nearly all mitotic cells contain condensed chromosomes
after 2-AP–induced override of VM-26 arrest in G2 (Fig.
2 B). In the chromosome spreads, cells with condensed
chromatin were scored for the presence of normally con-
densed chromosomes, as well as for incompletely con-
densed (axially elongated) chromosomes and for chroma-
tin exhibiting PCC. Reproducibly, 80% of such mitotic
cells yield chromosome spreads that contain normal ap-
pearing chromosomes. We conclude that VM-26 inhibition
of topo II enzyme activity does not prevent the formation
of chromosomes during checkpoint override. The chromo-
somes that form in the presence of 2-AP are not perfectly
intact, however. In comparison to chromosomes in no-
codazole-treated cells, some degree of chromosome frag-
mentation in cells treated with VM-26 and 2-AP is detect-
able by a small increase (z10%) in the apparent number
of chromosomes in spreads (data not shown).
At the maximum, 19.3% of the cells are in mitosis at 3 h
treatment with 2-AP (Fig. 1 B). However, cumulatively,
the majority of CHO cells finally override VM-26 arrest in
the presence of 2-AP. We have previously reported that
checkpoint override with 2-AP induces multinucleation as
a result of failure of cells to segregate chromosomes in
anaphase or to undergo cytokinesis (Andreassen and Mar-
golis, 1991, 1994). After 6 h of treatment with VM-26 and
2-AP, .85% of cells are micronucleated, indicating that
the majority of CHO cells have overridden G2 arrest by
this time point and have passed through mitosis.
To control for the possibility that a small amount of de-
catenation might continue in the presence of VM-26 and
that the cumulative decatenation might permit chromo-
some condensation, we designed a protocol to test for
chromosome formation after short exposures to VM-26
(Fig. 3 A). Cells were first synchronized at the onset of
S-phase by growth in isoleucine-deficient medium for 24 h
and then released into complete medium containing 2 mM
HU. A histogram of DNA content shows that the cells are
predominantly 2N in DNA content at the end of the HU
block (Fig. 3 A).
Cells were then released into drug-free medium. By 5 h
after release from HU, the cells have largely progressed
through S-phase and have nearly 4N DNA content. The
absence of MPM-2 signal (Fig. 3 A) indicates that the pop-
ulation has not yet entered mitosis at this time. Cells ex-
posed to VM-26 at 5 h after HU release uniformly exit
S-phase within 3 h and have 4N DNA content. MPM-2 sig-
nal is low, indicating the cells are arrested in G2 (Fig. 3 A).
The arrest imposed by VM-26 is stable, as the synchronous
population remains in G2 after 12 h of exposure to VM-26
(Fig. 3 A). In contrast, the control population continues to
cycle after release from HU and has largely progressed
through mitosis by 8 h, as indicated by the predominant
peak of cells with 2N DNA content (Fig. 3 A).
To demonstrate the ability of cells to form chromosomes
after brief exposure to VM-26, we blocked cells in G2 for 3 h
with VM-26, starting 5 h after release from HU and then
exposed them to 2-AP in the continuous presence of VM-26.
After such brief exposures to VM-26, cells yield chromo-
some spreads of normal appearance (Fig. 3 B).
We also used such presynchronized cells to address the
question of the stability of the VM-26 block. VM-26 inhib-
its DNA decatenation by stabilizing the covalent DNA–
topo II cleavage intermediate (Chen et al., 1984). The co-
valent DNA–topo II complex can be isolated by lysis of
blocked cells in the presence of denaturing detergent, fol-The Journal of Cell Biology, Volume 136, 1997 34
Figure 2. Condensed chromosomes form when CHO cells, blocked in G2 with VM-26, are induced to enter
mitosis with 2-AP. (A) Chromosome spreads of mitotic cells treated with VM-26 and 2-AP, and spreads from
untreated mitotic cells, or from cells arrested in mitosis with 0.20 mg/ml nocodazole. For comparison, images
are also shown of VM-26–treated G2 nuclei and of chromosome fragmentation in spreads from cells blocked
in S-phase with 2 mM HU and then advanced to mitosis by addition of 2-AP. (B) Quantitation of the per-
centage of VM-26–blocked cells, treated with 2-AP, that contain condensed chromosomes at mitosis.
Counts were made from chromosome spreads prepared by a 16 h block in VM-26, followed by a 3-h treat-
ment with both VM-26 and 2-AP. For comparison, the percentage of mitotic cells with incompletely con-
densed chromosomes or with fragmented chromosomes (PCC) were also quantitated. All data are derived
from three counts each of 150 or more mitotic cells. Bars: (lower left) 10 mm (for all panels except upper
right); (upper right) 20 mm.Andreassen et al. Chromosome Formation Independent of DNA Decatenation 35
lowed by separation of the DNA on a CsCl gradient (Trask
and Muller, 1988). Covalently associated topo II will mi-
grate with the DNA fractions of the gradient. We have
used this procedure to isolate the DNA–topo II complex
from synchronous cells exposed to VM-26 for varying
times in G2 (Fig. 4). DNA isolated from untreated cells mi-
grates to fractions 14–17, while DNA from cells treated for
.9 h with VM-26 migrates predominantly in fractions 15–18
(Fig. 4 A). DNA is well separated from the protein frac-
tions, which peak around fraction 5 (not shown).
We assayed for the presence of topo II in the DNA peak
fractions (14–18) by immunoblotting procedures, using
anti–topo II antibody as a probe (Fig. 4 B). Cells treated
with VM-26 for 6, 9, or 12 h beginning 5 h after release
from HU display strong signals for topo II conjugated with
DNA, whereas untreated cells (Fig. 4 B) show no signifi-
cant presence of topo II in these fractions. We scanned
these immunoblots to quantitate the relative level of topo
II present in the DNA fractions (Fig. 4 C). Importantly, we
find that the level of topo II in the DNA fractions is essen-
tially unchanged with time of exposure to VM-26. We con-
clude that VM-26 stably inhibits topo II activity in CHO
cells under conditions that permit the formation of com-
pact chromosomes after 2-AP induction. Further, we have
found (data not shown) that cells still largely in S-phase af-
ter 3 h treatment with VM-26 form substantially fewer co-
valent intermediates (18% of maximum values) by this as-
say. Therefore, we conclude that the formation of covalent
intermediates is specific to G2 DNA decatenation and is
not the result of random DNA damage.
The covalent DNA–topo II intermediate induced by VM-
26 results in double-strand DNA breaks that can readily
be detected by field inversion gel electrophoresis (FIGE)
(Charron and Hancock, 1990; Roberge et al., 1990). We
have used this technique as an additional assay of topo II
inhibition by VM-26 (Fig. 5 A). Treatment with 0.20 mg/ml
VM-26, the concentration used to bring about arrest of
CHO cells in G2, induces fragments of 200 kb and larger
(Fig. 5 A). The size and degree of fragmentation is equiva-
lent to that of samples treated with higher concentrations
of VM-26, ranging to 2.0 mg/ml. The only difference appar-
ent at higher concentrations of VM-26 is the generation of
small fragments that result from random breakage in addi-
tion to the population of 200-kb fragments generated from
DNA loops anchored by the chromosome scaffold (Char-
ron and Hancock, 1990). To avoid problems arising from
random breaks, we have used VM-26 at 0.20 mg/ml for
Figure 3. Condensed chromosomes form in CHO cells after 2-AP–
induced override of short-term arrest with VM-26. (A) Histo-
grams of DNA content (left) and two-dimensional dot plots of
MPM-2 versus DNA content (right). Cells arrested with 2 mM
HU were first presynchronized in G1 by growth in isoleucine-
deficient medium. Treatment with 0.20 mg/ml VM-26 beginning at
5 h after release from HU results in arrest at G2 with 4N DNA
content and low MPM-2 signal. (B) Condensed chromosomes
form in synchronous cells treated with VM-26 for 3 h when they
are induced to enter mitosis through checkpoint override by ad-
dition of 2-AP in the continued presence of VM-26 for 3 h. Cells
were released from HU for 5 h and then treated with VM-26 just
before arrival at G2. Bar, 10 mm.The Journal of Cell Biology, Volume 136, 1997 36
checkpoint override experiments. VM-26 at this concen-
tration is sufficient to stably block decatenation, as shown
by the constant levels of covalent intermediates generated
at different times of drug exposure (Fig. 4 C).
We have also used FIGE to verify inhibition of topo II
activity by VM-26 in CHO cells both during G2 arrest and
at mitosis after checkpoint override induced by 2-AP. (Mi-
totic cells were purified by mitotic shakeoff from the cul-
ture dish.) (Fig. 5 B). The degree of DNA cleavage and
size of the fragments generated (z200 kb) are equivalent
during G2 and in mitosis after checkpoint override. In con-
trast, fragmentation is minimally detectable in untreated
CHO cells or CHO cells treated with 10 mM 2-AP alone
(Fig. 5 B). We conclude that VM-26 suppresses DNA de-
catenation in G2 and that decatenation remains blocked in
mitosis after checkpoint override. From these results, it is
evident that apparently normal chromosomes routinely
form in VM-26 and 2-AP, although they contain frag-
mented DNA.
ICRF-193, another inhibitor of topo II activity, acts at a
different step in the topo II reaction pathway, locking the
enzyme in a “closed-clamp” conformation before DNA
cleavage or strand passage (Tanabe et al., 1991; Roca et al.,
1994). Exposure of CHO cells to 10 mM ICRF-193 for 16 h
results in a cell population with 4N DNA content and low
MPM-2 signal (Fig. 6 A). In certain cell types, ICRF-193
does not yield a G2 block. Instead, these cells pass through
mitosis without cytokinesis (Ishida et al., 1994). The DNA
content profile observed in Fig. 6 A could be consistent
with an effect of ICRF-193 on mitosis only, since in both
cases 4N DNA content is expected. We demonstrate, how-
ever, that under the experimental conditions applied here,
ICRF-193 induces an effective and complete G2 block. Re-
moval of ICRF-193 from the culture medium results in
progression into mitosis with a 4N DNA content and a
corresponding elevation in MPM-2 signal. If the cells had
not blocked in G2 but had instead passed through mitosis
without cell division, they would have an 8N DNA content
at the next mitosis after an intervening round of DNA rep-
lication. This is not observed. As observed with VM-26,
2-AP induces override of ICRF-193–dependent G2 arrest.
After addition of 2-AP, the blocked cells progress into mi-
tosis, accompanied by an elevation in the MPM-2 signal in
cells with 4N DNA content, as measured using two-dimen-
sional flow cytometry.
The percentage of mitotic cells, scored positive by the
presence of MPM-2 antigens and condensed chromatin,
peaked at 19.5% of the total population 3 h after 2-AP was
added in the continued presence of ICRF-193 (Fig. 6 B).
The time course and amplitude of 2-AP–induced override
of ICRF-193 arrest (Fig. 6 B) was similar to the time
course observed in 2-AP–induced override of VM-26 ar-
rest (Fig. 1 B). By contrast, cells in the continued presence
of ICRF-193 alone remain arrested in interphase.
Figure 4. VM-26 treatment stably maintains DNA–topo II cova-
lent complexes in G2-arrested cells. The unchanging presence of
covalent complexes indicates suppression of topo II activity. Co-
valent complexes of DNA and topo II were isolated on cesium
chloride gradients after lysis of cells in the presence of sarkosyl.
(A) The fractions containing DNA were identified by fluores-
cence measurement at an emission wavelength of 460 nm after
Hoechst 33258 staining. DNA was always confined to fractions
14–18 in repeated experiments. The fractions shown in anti–topo
II immunoblots are indicated with asterisks. (B) Topo II–DNA
complexes were assayed by anti–topo II immunoblots of fractions
containing DNA for cells exposed to 0.20 mg/ml VM-26 for 6, 9,
or 12 h after release from presynchronization with isoleucine-
deficient medium and then HU. A control, representing cells sub-
jected to synchronization but receiving no treatment with VM-26,
is also shown. (C) The relative levels of topo II present in com-
plexes with DNA were quantitated by scanning the dot blots in b
and integrating and summing the signals displayed by all the frac-
tions containing DNA.Andreassen et al. Chromosome Formation Independent of DNA Decatenation 37
ICRF-193 inhibits topoisomerase II at an earlier step
than VM-26, before the initiation of DNA strand breaks
(Tanabe et al., 1991; Roca et al., 1994). As expected from
its mechanism, ICRF-193 does not induce significant levels
of DNA strand breaks as measured by FIGE (data not
shown). Chromosome spreads were prepared to examine
chromosome formation in CHO cells after 2-AP–induced
override of G2 arrest with ICRF-193 (Fig. 7 A). Control
cells that remain arrested in G2 with ICRF-193 alone dis-
play normal interphase nuclei. In contrast, after induction
of mitosis by addition of 2-AP in the continued presence
of ICRF-193, the chromatin condenses into highly elon-
gated fibers composed of two parallel arms (Fig. 7 A).
Thus, ICRF-193 does not prevent the resolution of the
chromatin into a pair of elongated sister chromatids.
All the above observations have been made on CHO
cells. We have also observed similar chromosome conden-
sation in BHK cells on entry into mitosis after 2-AP–induced
Figure 5. VM-26 inhibits topo II activity both during G2 and at
mitosis induced by checkpoint override with 2-AP. Inhibition of
topo II activity was assayed by FIGE analysis of DNA fragments
formed by VM-26 stabilization of topo II–DNA covalent inter-
mediates. (A) The size and abundance of fragments is equivalent
for cells treated for 16 h with 0.20, 0.40, 0.80, or 2.0 mg/ml VM-26
(0.31, 0.61, 1.22, and 3.1 mM VM-26, respectively). (B) The size
and abundance of DNA fragments are equivalent, comparing G2
cells, obtained by 16 h of exposure to 0.20 mg/ml VM-26, with mi-
totic cells collected by selective detachment after 16 h of treat-
ment with VM-26 and then 3 h of exposure to VM-26 and 2-AP.
By comparison, fragmentation is minimal in untreated control
cells or in cells treated for 3 h with 2-AP alone.
Figure 6. 2-AP overrides ICRF-193–induced G2 arrest in CHO
cells. (A) Histograms of DNA content (left) and two-dimensional
dot plots of MPM-2 versus DNA content (right). Cells treated
with ICRF-193 alone for 16 h contain 4N DNA. After 16 h of
ICRF-193 treatment, cells enter mitosis when treated with both
ICRF-193 and 10 mM 2-AP for 3 h, as indicated by elevated
MPM-2 levels in cells with 4N DNA content. The result is equiva-
lent to mitotic entry observed after removal of ICRF-193 for 6 h.
(B) Quantitation of mitotic entry induced by 2-AP in ICRF-193–
blocked G2 cells. Mitotic cells were counted at the time points
indicated by microscopic assay, scoring cells with both elevated
MPM-2 levels and condensed chromatin, as detected by propid-
ium iodide stain. Cells were arrested for 16 h in ICRF-193 before
addition of 2-AP at the first time point. Each point represents
the average of three counts of at least 250 cells each. Standard de-
viations were always ,1.2% of the ordinate scale.The Journal of Cell Biology, Volume 136, 1997 38
override of VM-26 or ICRF-193–dependent G2 arrest (Fig.
7 B). As in CHO cells, condensed chromosomes form in
the combined presence of VM-26 and 2-AP. In the com-
bined presence of ICRF-193 and 2-AP, the chromosomes
that form consist of two elongated parallel fibers. The for-
mation of chromosomes with paired parallel fibers is strik-
ingly evident in an enlarged image of the same cell (Fig. 7
C). In the two cell types observed, DNA decatenation is
not required for chromosome formation, but the incom-
plete condensation of chromatin in ICRF-193 suggests
that full chromosome condensation may require topo II to
function in a nonenzymatic manner, since final condensa-
tion is inhibited by ICRF-193, but not by VM-26.
Topo II and ScII are the major proteins of the chromo-
some scaffold (Lewis and Laemmli, 1982). The presence of
these proteins in the chromosome scaffold suggests that
they play a role in the formation and organization of the
chromosome structure (Earnshaw and Heck, 1985; Earn-
shaw et al., 1985; Saitoh et al., 1994). We have therefore
examined chromosomes formed during override of G2
arrest to determine the distribution of topo II and ScII
(Fig. 8, A and B) and to quantitate their levels of associa-
tion with chromatin under various conditions (Fig. 8 C).
Confocal immunofluorescence microscopy (Fig. 8 A) dem-
onstrates that topo II is localized to the two axial cores
present within the arms of control chromosomes gener-
ated by mitotic arrest with nocodazole. Similarly, chromo-
somes formed in the presence of VM-26 and 2-AP display
two axial cores containing topo II. This result is striking, as
the two axial cores are present within chromosomes in
which the chromatid arms remain unseparated. Topo II is
similarly localized in unbroken double strands along the
length of the two parallel fibers formed during mitosis in-
duced in the presence of ICRF-193 and 2-AP.
We find that ScII displays the same pattern of distri-
bution within paired axial cores in control chromosomes, and
in chromosomes formed by G2 checkpoint override in the
presence of VM-26 and 2-AP (Fig. 8 B). Like topo II, ScII
is evident throughout the length of the long parallel fibers
generated after override of ICRF-193–dependent G2 ar-
rest. It is clear from these results that the association of
topo II and ScII with paired axial cores within the chromo-
some does not require DNA decatenation as a prerequisite.
Immunoblots performed on chromosomes, isolated from
mitotic cells generated by override of either VM-26 or
ICRF-193 G2 block, reveal that topo II and ScII are both
Figure 7. Partially condensed chromosomes containing two paired
arms form at mitosis after 2-AP–induced override of ICRF-193
G2 arrest. (A) Chromosome spreads of CHO cells treated with
ICRF-193 for 16 h and then for 3 h with both ICRF-193 and 2-AP
contain elongated chromosomes with two arms. In contrast, cells
treated with ICRF-193 alone contain only nuclei with uncon-
densed chromatin. (B) Spreads of chromosomes formed by BHK
cells arrested in G2 with VM-26 or ICRF-193 induced to enter mi-
tosis by addition of 2-AP. As in CHO cells, VM-26 does not in-
hibit full chromosome formation and ICRF-193 results in the for-
mation of elongated chromosomes with well-resolved parallel
arms. (C) Enlargement of chromosomes from same cell treated
with ICRF-193 and 2-AP, shown in part B. Chromosomes are vi-
sualized by staining with propidium iodide. Bars: (a and b) 10 mm;
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Figure 8. Both topo II and ScII are present in paired axial cores of chromo-
somes formed by addition of 2-AP after G2 arrest with either VM-26 or ICRF-
193. (A) Topo II (left) was immunolocalized in chromosome spreads of mitotic
cells treated with either nocodazole or both VM-26 and 2-AP, or both ICRF-193
and 2-AP. Chromosomes were visualized in images generated by counterstain-
ing with propidium iodide (right). (B) ScII (left) was immunolocalized in chro-
mosome spreads during mitotic arrest with nocodazole or after 2-AP–induced
override of G2 arrest with VM-26 or ICRF-193. Primary rabbit antibodies
against topo II and ScII were detected with FITC-conjugated goat anti–rabbit
secondary antibodies. (C) Immunoblots of isolated chromosomes and nuclei
demonstrate that topo II is present at equivalent levels both during G2 arrest
with topo II inhibitors and in mitosis after 2-AP–induced checkpoint override
of G2-arrested cells. By contrast, ScII is present in chromatin only in mitosis ei-
ther in normal mitotic cells or after 2-AP override of G2 arrest induced by in-
hibitors of topo II. Bar, 10 mm.The Journal of Cell Biology, Volume 136, 1997 40
present at levels comparable to control levels obtained
with chromosomes isolated from nocodazole-blocked cells
(Fig. 8 C). Topo II, but not ScII, is present in G2 nuclei
during arrest with either VM-26 or ICRF-193. The level of
topo II in these nuclei is indistinguishable from the
amount of topo II present in chromosomes isolated after
override of G2 arrest. Thus, during G2, topo II is already
present at levels required to participate structurally in the
formation of the chromosome, but ScII is specifically re-
cruited to the chromosome during mitotic onset. The pres-
ence, quantity, and distribution of both topo II and ScII in
the chromosomes after checkpoint override indicates that
the chromosomes formed during checkpoint override con-
tain two independent axial cores. Further, it is apparent
that, before DNA decatenation in G2, topo II is already in
a position to participate in formation of chromosomes
with two axial cores.
Discussion
Mammalian cells possess a G2 checkpoint that requires
topo II–dependent decatenation of sister DNA duplexes
prior to entry into mitosis (Downes et al., 1994). Here we
demonstrate that chromosomes with a two-armed axial
core (chromosome scaffold) form in the absence of DNA
decatenation after G2 checkpoint override induced by the
protein kinase inhibitor 2-AP. Thus, while topo II–depen-
dent DNA decatenation is normally required to satisfy the
G2 checkpoint for progression into mitosis, its activity is
not required to form the chromosome scaffold at mitosis.
This suggests that topo II plays a noncatalytic structural
role in chromosome condensation. The chromosome scaf-
fold is present as an axial proteinaceous core within chro-
mosomes in diverse systems (Adolph et al., 1977; Paulson
and Laemmli, 1977; Klein et al., 1992; Hirano and Mitchi-
son, 1994). We find that the two major scaffold proteins
present in mammalian chromosomes, topo II and ScII
(Lewis and Laemmli, 1982), are present in paired axial cores
in chromosomes formed without DNA decatenation. Our
results strongly suggest that the template for the chromo-
some structure has been put in place before the DNA de-
catenation event in G2. We propose a model in which the
scaffold is established by association of topo II with newly
synthesized DNA as it is replicated during S-phase.
Mitotic Entry Is Regulated by a Topo II–dependent 
Checkpoint in G2
We have demonstrated, by flow cytometric analysis, that
CHO cells arrest indefinitely in G2 in the presence of the
topo II inhibitors VM-26 or ICRF-193 but can be induced
by the protein kinase inhibitor 2-AP to enter mitosis when
topo II activity is suppressed. VM-26 inhibits topo II at an
intermediate step, in which it is covalently linked with
cleaved DNA (Chen et al., 1984). VM-26–induced G2 ar-
rest could therefore arise either through checkpoint re-
sponse to DNA damage or failure of DNA decatenation
(Lock and Ross, 1990). By contrast, ICRF-193 induces G2
arrest without inducing DNA breaks (Ishida et al., 1991;
Tanabe et al., 1991). Downes et al. (1994) observed a G2
delay induced by ICRF-193, and on this basis they con-
cluded that a DNA decatenation checkpoint exists in G2.
As we show here, while topo II–dependent DNA decat-
enation is not physically required for chromosome con-
densation in mammalian cells, it is required both to pass
the G2 decatenation checkpoint and for chromosome seg-
regation during mitosis. Since there appears to be no DNA
decatenation checkpoint during mitosis (Uemura et al.,
1987; Downes et al., 1991; Shamu and Murray, 1992), the
G2 checkpoint may serve to assure that decatenation is
sufficient both to permit DNA condensation without
strand breaks and to permit normal chromosome segrega-
tion in mitosis.
We find that CHO cells are stably arrested in G2 with ei-
ther VM-26 or ICRF-193 and that mitotic entry in their
continued presence requires checkpoint override by 2-AP,
accompanied by activation of p34cdc2 kinase. Thus, topo
II–dependent DNA decatenation in G2 is a prerequisite
for the activation of p34cdc2 kinase and mitotic entry. Since
chromosome formation normally occurs only upon entry
into mitosis, inhibition of mitotic entry by the DNA decat-
enation checkpoint indefinitely inhibits chromosome for-
mation.
The p34cdc2 protein kinase is cyclically activated to in-
duce mitosis during the eukaryotic cell cycle (Norbury and
Nurse, 1992). We have previously shown that 2-AP expo-
sure leads to the inactivation of p34cdc2 kinase during over-
ride of mitotic arrest with taxol or nocodazole (Andreassen
and Margolis, 1994). Here, we show that p34cdc2 kinase,
which is inactive during G2 arrest with VM-26 or ICRF-
193, is activated at mitosis after the induction of check-
point override by 2-AP. Thus, taken together, these results
show that 2-AP neither directly activates nor inactivates
the p34cdc2 kinase but instead acts to suppress checkpoint
controls.
DNA Decatenation Is Not Required for
Chromosome Condensation
Our results demonstrate that DNA decatenation is not re-
quired for the formation of the two-armed chromosome
scaffold (axial core) that is characteristic of paired sister
chromatids at mitosis. We base this conclusion on our ob-
servation that two-armed axial cores form when cells are
induced to enter mitosis by 2-AP treatment, while DNA
decatenation is continuously blocked by either VM-26 or
ICRF-193.
Previous studies have shown that topo II is required for
chromosome condensation in Xenopus mitotic extracts in
vitro (Newport and Spann, 1987; Adachi et al., 1991; Hirano
and Mitchison, 1993). Such studies, however, have led to
different conclusions as to the specific role that topo II
might play in chromosome formation. In one study, after
immunodepletion of topo II, addition of a high level of
topo II was required for chromosome condensation, sug-
gesting that topo II plays a structural role in chromosome
formation (Adachi et al., 1991). Authors of another study,
by contrast, concluded on the basis of VM-26 inhibition of
chromosome condensation in mitotic extracts that chro-
mosome condensation requires topo II enzymatic activity
(Newport and Spann, 1987).
Because the above experiments were performed with
exogenously added mitotic extracts containing active p34cdc2
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requirement to overcome a G2 DNA decatenation check-
point. Further, since such in vitro studies (Newport and
Spann, 1987; Adachi et al., 1991; Hirano and Mitchison,
1993) used G1 nuclei, they were unable to assess the role of
topo II in the formation of two-armed chromosome mor-
phology. In contrast to these previous studies, our analysis
has uniquely permitted dissection of the role of topo II in
checkpoint control and has permitted study of the capacity
to form two-armed chromosomes in the absence of DNA
decatenation.
We have presented evidence that, in intact cells, topo
II–dependent decatenating activity is not required for the
formation of chromosomes with paired arms. ICRF-193
inhibits topo II before the initiation of DNA decatenation
and does not induce DNA strand breaks (Ishida et al.,
1991; Tanabe et al., 1991; Roca et al., 1994). We find that
chromosomes with highly elongated parallel arms form in
the presence of ICRF-193 and 2-AP. Recently, it has been
demonstrated that antibodies to XCAP-C, a protein pres-
ent in cores of chromosomes formed in Xenopus extracts
in vitro, block a late step in chromosome condensation
(Hirano and Mitchison, 1994), yielding chromosomes with
elongated fibers. Since these results are similar to what we
have observed in mammalian cells treated with ICRF-193
and 2-AP, we suggest that topo II plays a nonenzymatic
role in completing a final step in chromosome condensa-
tion.
Perhaps the chromosome core itself undergoes a self-
assembly step involved in final compaction of the chromo-
some (Hirano and Mitchison, 1994). Consistent with this
possibility, topo II can selectively bind and aggregate scaf-
fold attachment region (SAR) sites in vitro (Adachi et al.,
1989). Further, topo II self-associates in a phosphoryla-
tion-dependent manner in vitro (Vassetzky et al., 1994).
ScII, a major protein of the chromosome scaffold, forms a
complex with topo II (Ma et al., 1993) and associates with
chromatin only during mitosis (Saitoh et al., 1994). Thus,
ScII might interact with topo II specifically to form the
mature chromosome structure during mitosis. Impor-
tantly, both topo II and ScII are present in continuous, but
elongated, chromosome cores in mitotic cells after treat-
ment with ICRF-193 and 2-AP. It is possible that ICRF-
193 disrupts the interaction of topo II with a chromosome
core protein (perhaps ScII) that is necessary for final con-
densation of both the axial core and of the chromosome.
In contrast to results with ICRF-193 and 2-AP, which
suggest that topo II–dependent decatenation might be re-
quired to obtain complete chromatin condensation, our re-
sults from cells treated with VM-26 and 2-AP indicate that
the DNA decatenating activity of topo II is not required to
completely condense chromosomes. VM-26 directly inhib-
its DNA decatenation by preventing topo II strand pas-
sage, inducing a covalent complex of enzyme and cleaved
DNA (Chen et al., 1984; Osheroff, 1989). Despite the inhi-
bition of decatenation, condensed chromosomes form in
the continued presence of VM-26 after 2-AP–induced
checkpoint override. Thus, the continued catenated state
of duplex DNA strands does not prevent chromosome
condensation, suggesting that chromosome structure is
templated before, and independently of, DNA decatena-
tion. Our results suggest that, while VM-26 directly inhib-
its DNA decatenation, it does not interfere with the non-
enzymatic structural role of topo II, thereby permitting
complete chromosome condensation.
We have verified by several criteria that condensed
chromosomes form despite efficient inhibition of DNA
decatenation by VM-26. Double strand breaks at topo II
cleavage sites result in DNA fragments of relatively uni-
form size that can be resolved by FIGE. The size of such
fragments is z200 kb at 0.20 mg/ml VM-26, corresponding
roughly to the size of DNA loops anchored by topo II
(Charron and Hancock, 1990). The SAR sites that bind
topo II and anchor the DNA loops appear to be the essen-
tial target of topo II–dependent DNA decatenation during
G2 (Adachi et al., 1989; Strick and Laemmli, 1995). Use of
higher VM-26 concentrations does not change the abun-
dance of these loop fragments but does generate smaller
fragments, which probably represent nonspecific DNA
cleavage intermediates (Fig. 5; Ross et al., 1984). Newport
and Spann (1987) demonstrated that 10 mM VM-26 inhib-
its chromosome condensation in Xenopus extracts. This
high concentration of VM-26 may have induced the for-
mation of nonspecific (non-SAR) covalent intermediates
that interfered with chromosome condensation. Our FIGE
results demonstrate that DNA decatenation is blocked by
VM-26 in G2 and remains blocked in mitosis after check-
point override by 2-AP. Thus, FIGE demonstrates that
DNA decatenation remains inhibited after checkpoint
override and that chromosomes form with fragmented
DNA in the presence of VM-26 and 2-AP. In this context,
it is important to note that such chromosomes contain in-
tact paired axial cores that must be functioning here to
maintain the integrity of the chromosome structure.
We have also addressed the stability of the VM-26 block
by quantitating the covalent DNA–topo II complex that
forms in the presence of VM-26 (Fig. 4). The level of
cleavage intermediates remains unchanged during 6 h of
arrest in G2. If inhibition of topo II–dependent DNA de-
catenation were incomplete, the level of topo II found in a
covalent complex with DNA would have been expected to
diminish. We have found, interestingly, that cells exposed
to VM-26 in S-phase show minimal formation of topo II–
DNA covalent intermediates (unpublished observations),
indicating that this assay is an accurate measure of decate-
nation specific to G2 at the drug concentration used.
The Chromosome Structure Is Templated
before Mitosis
We find that formation of the two-armed chromosome
scaffold does not require DNA decatenation. Paired axial
cores are present in cells that lack chromatid resolution af-
ter treatment with VM-26 and 2-AP, and in the partially
condensed chromosomes that form after ICRF-193 and
2-AP treatment. These results suggest that the chromo-
some scaffold, and the structure of the chromosome itself,
is templated before the DNA decatenation event in G2.
There is abundant evidence that the chromosome scaffold
may determine the structure of the chromosome.
The fact that two axial cores are present in chromo-
somes that lack distinct chromosome arms in cells treated
with VM-26 and 2-AP demonstrates that the paired axial
cores can exist before chromosome arm separation. This
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derlies the chromosome morphology, in accord with re-
sults showing that the chromosome scaffold maintains the
morphology of the chromosome when DNA is digested or
histones are extracted (Adolph et al., 1977; Paulson and
Laemmli, 1977; Earnshaw et al., 1985). Such a possibility is
also supported by the recent demonstration that XCAP-C,
which is a core protein in chromosomes assembled in vitro
in  Xenopus extracts, plays a role in both forming and
maintaining chromosome organization. Antibody blocking
of XCAP-C results in loss of chromosome organization
and the appearance of elongated chromosome fibers
(Hirano and Mitchison, 1994), similar to those created by
combined ICRF-193 and 2-AP treatment. We have found
that both topo II and ScII are present in highly elongated
chromosome arms after treatment with ICRF-193 and 2-AP.
This result demonstrates that an intermediate-stage axial
core exists before final condensation of the chromosome,
and also demonstrates that both topo II and ScII can be
present in such intermediate fibers.
Recently Gimenez-Abian et al. (1995) have reported
that Indian Muntjac chromatid cores separate during mi-
tosis and that the separation is inhibited by ICRF-193. By
contrast, our results show that topo II–dependent events
required for separation of chromatid cores have occurred
by G2. It is possible that the requirements for topo II–
dependent resolution of chromatid cores are different in
Indian Muntjac and CHO cells. CHO cells arrest stably in
G2 in response to ICRF-193, whereas Indian muntjac cells
arrest in mitosis (Gimenez-Abian et al., 1995). Alterna-
tively, it is possible that the template for core separation
has been completed at the molecular level during interphase
but becomes manifest during mitosis. In this respect, it should
be noted that Indian Muntjac chromatid cores do com-
pletely separate in a time-dependent manner in the contin-
ued presence of ICRF-193 (Gimenez-Abian et al., 1995).
We present a model (Fig. 9) in which topo II associates
with the daughter DNA duplexes in a semiconservative
manner during DNA replication. Topo II can bind DNA
through SARs (Gasser and Laemmli, 1986; Adachi et al.,
1989). We propose that topo II remains associated with
SAR sites of the parental DNA strand and that topo II
also associates with SAR sites that are generated on
daughter DNA strands during DNA replication. In this
manner, the process of DNA replication yields indepen-
dent templates for condensation of the sister DNA du-
plexes, such as those we have observed in cells treated
with ICRF-193 and 2-AP. This model suggests that auton-
omous organization of the sister duplexes is templated by
their independent associations with topo II and are there-
fore preorganized for chromosome condensation. By this
model, final condensation of the chromosome would in-
volve compaction of the topo II–associated axial cores,
bringing with them condensed DNA loops that are an-
chored to topo II.
In support of this model, topo II binds to DNA through
SAR sites both in interphase nuclei and mitotic chromo-
somes (Berrios et al., 1985; Mirkovitch et al., 1988), and
topo II accumulates in the nuclei of proliferating cells at
S-phase (Heck and Earnshaw, 1986). Furthermore, topo II
is a component of the interphase nuclear matrix that sup-
ports DNA replication (Hozàk et al., 1993). Thus, topo II
is positioned to associate with newly generated SAR sites
at their site of synthesis. We have shown that the levels of
DNA-associated topo II are equivalent in nuclei arrested
in G2 and in mitotic chromosomes. This result supports the
possibility that the template for chromosome condensa-
tion is already in place in cells arrested in G2 with inhibi-
tors of topo II. In accord with Saitoh et al. (1994), we find
that ScII only associates with mitotic chromosomes, and
thus represents a mitotic factor that integrates with the
topo II–based template to form the condensed and or-
dered chromosome.
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